Mylan’s ‘Biosimilar’ Drug Comparable to Roche Cancer Medicine
Study Finds Mylan’s ‘Biosimilar’ Drug Comparable to Roche Cancer Medicine Development marks milestone in effort to bring cheaper versions of cancer treatments to market. Mylan Pharmaceuticals Inc. is developing Myl-1201O, which a study showed to be essentially equivalent in safety and effectiveness to Roche Holding AG’s Herceptin. PHOTO: GETTY IMAGES Researchers said a drug being developed by Mylan Pharmaceuticals Inc. proved comparable to Roche Holding AG’s Herceptin in a clinical trial, a new milestone in the effort to bring cheaper versions of some of biotechnology’s best-known cancer drugs to the market. In a study involving a total of 500 patients, Mylan’s drug, called Myl-1401O, was shown to be essentially equivalent in safety and effectiveness to Herceptin, a multibillion-dollar medicine that in the past two decades has transformed treatment for about 25% of breast cancer patients. Mylan’s drug is a so-called biosimilar—the industry’s term for a copy of ...